The a2 Milk Company Limited has previously commented that the infant formula regulatory environment in China continues to evolve and the Company considers itself well placed to respond to announced changes in regulation in conjunction with its manufacturing partner.
Recent changes have been announced by Chinese regulators concerning taxation of Cross-Border E-Commerce (CBEC) Traded Commodities, and the publication of product lists (“Positive Lists”) for CBEC traded commodities through China free trade zones.
The Company welcomes the increasing level of clarity around changes for this channel recently announced, including that infant formula and whole milk powder products are included on the “Positive Lists” and that infant formula products sold in China have until 1 January 2018 to complete formulation registration with CFDA (China Food and Drug Administration).
Further, the Company is today conducting a media event in Beijing involving the publication of a new human research study conducted in China around symptoms of lactose intolerance and the benefits of a2 Milk™. A copy of the media release is attached for information.
For further information contact:
The a2 Milk Company Limited
Managing Director and CEO
+61 2 9697 7000